诺华制药(NVS.US)重磅核药在华获批新适应症

智通财经
Aug 26
【诺华制药(NVS.US)重磅核药在华获批新适应症】智通财经APP获悉,8月25日,诺华制药(NVS.US)宣布镥[177Lu]特昔维匹肽(中文商品名:派威妥)在华获批新适应症,用于联合雄激素受体通路抑制剂(ARPI)治疗前列腺特异性膜抗原阳性(PSMA+)转移性激素敏感性前列腺癌(mHSPC)患者。这是该药物在国内获批的第三项适应症,目前其可用于所有阶段的PSMA+转移性前列腺癌患者——从mHSPC到转移性去势抵抗性前列腺癌(mCRPC)、覆盖化疗前至化疗后多个关键治疗阶段。此外,诺华近日也在国内递交了该药物的地产化生产申请。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10